Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 8NETWORK 8NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Multiple Myeloma 14Lymphoma, Non-Hodgkin 12Leukemia, Myeloid, Acute 12Leukemia 5Hodgkin Disease 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Chemotherapy-induced Neutropenia 3Breast Neoplasms 3Small Cell Lung Carcinoma 2Plasmacytoma 2Paraproteinemias 2Neutropenia 2Neoplasm Metastasis 2Leukemia, Plasma Cell 2Chemotherapy Induced Neutropenia 2Carcinoma, Non-Small-Cell Lung 2Unspecified Adult Solid Tumor, Protocol Specific 1Triple Negative Breast Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms by Histologic Type 1Neoplasms 1Myelodysplastic Syndromes 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Promyelocytic, Acute 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

Doxorubicin 33pembrolizumab 16Gemcitabine 15eribulin 10Irinotecan 10olaratumab 9Trabectedin 9pazopanib 8Docetaxel 8Injections 7Cyclophosphamide 7Nivolumab 6Fluorouracil 6anlotinib 5Temozolomide 5Ipilimumab 5Ifosfamide 5Bevacizumab 5tazemetostat 4ridaforolimus 4Drug Therapy 4Cetuximab 4Carboplatin 4toripalimab 3surufatinib 3spartalizumab 3ganitumab 3entrectinib 3conatumumab 3belinostat 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Sarcoma × Granulocyte Colony-Stimulating Factor × Clear all
NCT07602777 2026-05-22

A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)

GlaxoSmithKline

Phase 1/2 Not yet recruiting
113 enrolled
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡